Filing Details
- Accession Number:
- 0001140361-13-013358
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-03-20 15:39:10
- Reporting Period:
- 2013-03-18
- Filing Date:
- 2013-03-20
- Accepted Time:
- 2013-03-20 15:39:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1274826 | Robert Baffi | C/O Biomarin Pharmaceutical Inc. 105 Digital Drive Novato CA 94949 | Evp, Technical Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-03-18 | 20,000 | $14.39 | 72,350 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-03-18 | 20,000 | $61.02 | 52,350 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) Common Stock | Disposition | 2013-03-18 | 20,000 | $0.00 | 20,000 | $14.39 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 50,000 | 2009-11-12 | 2019-05-11 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 8,238 | Indirect | Shares held by Baffi Family Trust |
Footnotes
- Transaction made pursuant to a Rule 10b5-1 plan executed on March 4, 2013.
- The price in Column 4 is a weighted average price. The prices actually received ranged from $61.00 to $61.10. The reporting person will provide to the issuer, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Options vest on November 12, 2009 and 1/48th on the 12th of each month thereafter.
- Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.
Billionaire Hedge Funds
